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Abstract
Background Controversies on how to treat upper eso-
phageal carcinoma have existed for several decades. With
the application of minimally invasive techniques, surgical
treatment to upper esophageal carcinoma tends to show
more advantages and attract more patients. Up to now,
most hospitals adopted the combined thoracoscopic and
laparoscopic esophagectomy (CTLE) as the way of mini-
mally invasive surgery for upper esophageal carcinoma.
But CTLE to treat upper esophageal carcinoma has its
drawbacks, such as demanding certain pulmonary function
and severe postoperative regurgitation. In 2011, we
developed the gasless laparoscopic transhiatal esophagec-
tomy (LTE) to treat upper esophageal carcinoma, which
showed some advantages. The aim of this article was to
compare LTE with CTLE in treating upper thoracic or
cervical esophageal carcinoma and assess the value of
LTE.
Methods From 2009 to 2014, esophagectomy has been
performed by the introduction of minimally invasive sur-
gery in a total of 83 patients with upper thoracic or cervical
esophageal carcinoma. Among these patients, LTE was
performed in 27 cases (Group 1), while CTLE was per-
formed in the other 56 (Group 2). Neoadjuvant
chemotherapy was done in patients of Group 1.
Results There were no operation-related deaths and con-
version to open procedure. There was no significant dif-
ference in postoperative complications, ventilation time,
ICU stay, hospital stay, and anastomotic leak rates between
the two groups. But LTE was associated with shorter
operative time and less intraoperative blood loss. In Group
2, 21 (37.5 %) patients had postoperative pulmonary
complications, while in Group 1, there were 6 (22.2 %)
patients having pulmonary complications at least one time.
Results of 24-h pH monitoring and manometry showed that
postoperative laryngo-pharyngeal reflux (PLPR) was more
severe in Group 2 patients than in Group 1; for Group 1,
PLPR mainly occurred on sleep stage, while for Group 2,
PLPR might exist all the day with short intervals and last
longer at night. The median overall survival was
27.2 months after CTLE and 30.8 months after LTE
(P = 0.962). There was no significant difference in sur-
vival at 2, 3 and 4 years between the two groups.
Conclusions Compared with CTLE, LTE is a more
minimally invasive approach to effectively treat patients
with upper esophageal carcinoma. Laryngo-pharyngeal
reflux after LTE was less severe than that after CTLE,
which might lower incidence of pulmonary complications.
For the elderly patients, LTE seems more suitable.
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and Other Interventional Techniques 
Controversies on how to treat upper esophageal carcinoma
have existed for several decades. Some experts believed
that surgery and radiotherapy to upper esophageal carci-
noma could lead to equivalent results, and both of them had
pros and cons [1–7]. Radiotherapy had lower rates of
morbidity and mortality [1–4], while surgery might result
in long-term outcome [5–7]. But with the application of
minimally invasive techniques, surgical treatment to upper
esophageal carcinoma tends to show more advantages and
attract more patients [8, 9]. Up to now, most hospitals
adopted the combined thoracoscopic and laparoscopic
esophagectomy (CTLE) as the way of minimally invasive
surgery for upper esophageal carcinoma. But CTLE to treat
upper esophageal carcinoma has its drawbacks, such as
demanding certain pulmonary function and severe post-
operative regurgitation [8, 10–12]. In 2011, the gasless
laparoscopic transhiatal esophagectomy (LTE) to treat
upper esophageal carcinoma was developed in our
department, which showed some advantages. It could be
performed for the elderly or patients with severe preoper-
ative pulmonary dysfunction. The aim of this article was to
compare LTE with CTLE in treating upper thoracic or
cervical esophageal carcinoma and assess the value of
LTE.
Materials and methods
From 2009 to 2014, esophagectomy has been performed by
the introduction of minimally invasive surgery in a total of
83 patients with upper thoracic or cervical esophageal
carcinoma. Cervical esophageal carcinoma accounted for
61.4 %, and upper thoracic esophageal carcinoma
accounted for 38.6 %. Among these patients, the gasless
laparoscopic transhiatal technique (LTE) was performed in
27 cases (Group 1), while a combined laparoscopic and
thoracoscopic technique (CTLE) was used in the other 56
(Group 2) (Table 1). Neoadjuvant chemotherapy was done
in patients of Group 1. There were 13 cases in whom
observed tumors obviously shrunk after neoadjuvant
chemotherapy (Fig. 1). Among them, esophageal carci-
noma with local advance downstaged effectively in 11
cases. LTE was done within 4 weeks after completion of
neoadjuvant chemotherapy. No one received preoperative
radiotherapy.
Endoscopy with biopsy was performed before surgery
and histologic examination confirmed that all were squa-
mous cell carcinoma. Computed tomography (CT scan),
ultrasonography, barium esophagram and bronchoscopy
were routinely undertaken on all patients to stage preop-
eratively and confirm the absence of contra-indications for
thoracoscopy and laparoscopy. Endoscopic ultrasound
(EUS) was done to obtain accurate locoregional staging in
56.6 % patients, and positron emission tomography scan
(PET) data were obtained in 34.9 % patients. But 7 patients
could not afford the costs of EUS or PET, so we had to rely
on CT to judge the tumor stage.
The study was approved by the Human Research Ethics
Board of Beijing Tongren Hospital, Capital Medical
University, and Cancer Institute and Hospital, Chinese
Academy of Medical Sciences. Patients were warned in
regard to the potential risks prior to surgery and signed
consent forms if they agreed to undergo esophagectomy by
minimally invasive techniques.
Follow-up
Patients with upper thoracic or cervical esophageal carci-
noma received adjuvant chemotherapy after LTE or CTLE.
All patients were followed up at the outpatient clinic for
the first 3 months after surgery, and then in intervals of
6 months during the postoperative 5 years. In order to
objectively measure postoperative reflux, postoperative
24-h pH monitoring and manometry were undertaken and
documented between 6 months and 1 year after surgery.
Surgical technique
1. The combined laparoscopic and thoracoscopic tech-
nique was performed as Luketich prescribed previ-
ously [8].
2. The gasless laparoscopic transhiatal esophagectomy
was performed with five upper abdominal laparoscopic
incisions and a 4-cm-long left cervical incision.
Patients were intubated under general single-lumen anes-
thesia, and placed in a supine position with legs spread
(20–30). At the first stage, the isobaric laparoscopy using
abdominal wall lifting (Mizuho Ika Kogyo CO. LTD,
Japan) was established (Fig. 2). Besides a 4-cm-long
midline incision below subxyphoid made to facilitate a
cotton tape and a Gauze pad into the abdomen, there were
other four trocars (one 10-mm trocar and three 5-mm tro-
cars) placed. The first step is to mobilize the stomach with
the ultrasonic coagulating shears. The gastrocolic omentum
is divided with care taken to preserve the right gastroepi-
ploic arcade. Special attention should be paid when
dividing the short gastric vessels. The stomach is retracted
inferiorly; the short gastric vessels are identified and then
divided cautiously with the ultrasonic coagulating shears.
Next, the gastrohepatic ligament was opened widely. The
dissection then was carried up and down the right and left
crura and into the lower mediastinum. The entire periphery
of the abdominal esophagus was separated.
The left gastric artery and vein could be exposed from
the lesser curve view and transected at its origin with the
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Endo-GIA vascular stapler. A 5-cm-wide gastric tube was
constructed by firing a linear stapler 3–4 times along the
greater curve of the stomach from the angle at the lesser
curve to the top of the fundus.
After left-sided mobilization of the cervical esophagus,
the intrathoracic normal esophagus was bluntly resected
from the neck to the upper mediastinum.
At the same time, the lower esophagus was transected at
the gastro-esophageal junction with the ultrasonic coagu-
lating shears. A cotton tape was sutured to the nasogastric
tube and was pulled up through the mediastinal esophagus
to the neck. At the transected gastro-esophageal junction,
the cotton tape was attached to the distal esophagus by two
stitches. A surgeon held traction to the cotton tape and
pulled distal esophagus up through the posterior medi-
astinum to the neck, followed by a Gauze pad to press the
periesophageal plane. Meanwhile, the reconstructed gastric
tube was stitched to the cotton tape and 3–5 min later was
Fig. 1 Upper esophageal carcinoma with local advance downstaged
effectively after neoadjuvant chemotherapy (the right picture was
taken before neoadjuvant chemotherapy; the left one after neoadju-
vant chemotherapy)
Fig. 2 Isobaric laparoscopy using abdominal wall lifting was
established
Table 1 Characteristics of
patients with upper esophageal
cancer undergoing LTE or
CTLE




Median age (range) 72 (47–89) 61 (41–78)
Tumor site
Cervical esophagus 19 31





Mean operative time (minute) 131 ± 29 175 ± 15
Intraoperative blood loss (ml) 189 ± 52 336 ± 87
Histologic type Squamous cell carcinoma Squamous cell carcinoma
No. of lymph nodes dissected 7 (3–18) 18 (11–26)
Ventilation time—days (range) 1 (0–5) 2 (0–6)
ICU stay—days (range) 1 (0–6) 2 (0–7)
Hospital stay—days (range) 12 (11–27) 13 (11–33)
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drawn up through the posterior mediastinum to the neck.
Esophagogastrostomy was performed in the neck, with
cervical lymphadenectomy.
Endpoint
Primary endpoints were as follows: overall survival (OS:
defined as the time interval between surgery and all deaths)
and postoperative laryngo-pharyngeal reflux (PLPR)
(which may affect quality of life).
Secondary endpoints were as follows: the major post-
operative morbidity rate (major complications occurring
within 30 postoperative days and during follow-up,
respectively).
Statistical analyses
Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS, ver. 13.0). All
continuous data are expressed as a mean ± standard
deviation. The impact of surgery was estimated in uni-
variate analysis. Comparisons were performed on patients
with surgical treatment. Where applicable, Chi-square and
Student’s t tests were used; survival was measured from the
day of the operation until death or the last follow-up visit.
Kaplan–Meier survival curves were used to compare dif-
ferent survival between the two groups. P values less than
0.05 were considered significant.
Results
Esophagectomy by minimally invasive surgery has been
successfully completed in all patients. There were no
operation-related deaths and conversion to open procedure.
The margin of resection was clear of tumor in all patients.
Mean operative time was 131 ± 29 min in Group 1, while
it was 175 ± 15 min in Group 2 (P = 0.005). Mean
intraoperative blood loss in Group 1 was 189 ± 52 ml,
significantly less than 336 ± 87 ml in Group 2(P = 0.001)
as shown in Table 1. There was no significant difference in
postoperative complications, ventilation time, ICU stay,
and hospital stay between the two groups. Within 1 month
after LTE, there were 7 cases having postoperative com-
plications (Table 2): Anastomotic leakage occurred in 3
(11.1 %) cases, pulmonary complications in 2 (7.4 %)
case, cardiac complications in 2 (7.4 %) cases and herni-
ation of part of the colon into the right thorax in one case
(3.7 %), 4 patients received postoperative auxiliary radio-
therapy; within 1 month after CTLE, postoperative com-
plications happened in 23 patients (Table 2): Anastomotic
leakage occurred in 8 (14.3 %) cases, pulmonary compli-
cations in 8 (14.3 %), cardiac complications in 7 (12.5 %)
and vocal-cord paralysis in one case (2.8 %), and nine
patients received postoperative auxiliary radiotherapy. All
the cases with anastomotic leakage were successfully
managed within 30 days after surgery.
Follow-up was complete for all patients. Patients in
Group 1 were followed up for 1–4 years, while the follow-
up period in Group 2 was 1–5.5 years. The median disease-
free survival was 30.2 months in Group 1 and 26.4 months
in Group 2 (P = 0.933). For Group 1 and Group 2,
recurrence occurred in 48.1 % (13/27) and 51.8 % (29/56)
of patients, respectively (P = 0.756). Survival analysis by
Kaplan–Meier’s method showed no statistically significant
difference between Group 1 and Group 2. The curves for
disease-free (Fig. 3) and overall survival (Fig. 4) were
similar after surgery without a difference favoring one
technique over the other. The median overall survival was
27.2 months after the CTLE and 30.8 months after the
laparoscopic transhiatal esophagectomy (P = 0.962). 2-, 3-
and 4-year survival rates in Group 1 were 56.2, 42.5 and
32.1 %, respectively, While in Group 2, 2-, 3-, 4- and
5-year survival rates were 61.9, 34.9, 29.2 and 19.5 %,
respectively. There was no significant difference in sur-
vival at 2, 3 and 4 years between the two groups. In Group
1, among 11 deaths, eight were associated with recurrence
or metastasis and three were due to heart failure. In Group
2, 23 patients died of recurrence or metastasis, three deaths
were attributable to pulmonary complications, two died of
portal vein thrombosis, and one death was related to heart
failure.
All the patients complained about heartburn and regur-
gitation from time to time after surgery. Major complica-
tions more than 6 months after surgery were pneumonia
and anastomotic stricture (Table 2): in Group 1, there were
4 patients having pulmonary complications at least one
time and 4 patients experiencing anastomotic stricture,
while in Group 2, 13 patients had postoperative pulmonary
complications (P = 0.374) and seven had postoperative
anastomotic stricture (P = 0.771). Anastomotic stricture
was managed successful by anastomotic dilatations.
Results of postoperative 24-h pH monitoring and
manometry were documented as shown in Table 3. Maybe
due to short length of residual esophagus, no consistent
motility pattern was detected. PLPR was more severe in
Group 2 than in Group 1: By univariate analysis, the total
number of reflux events (pH\ 4), the number of reflux
episodes (lasting[ 5 min) and the reflux time in Group 1
were less than those in Group 2 (P = 0.00), while the
longest episode of reflux in Group 1 was longer than that in
Group 2 (P = 0.01). 24-hour ambulatory esophageal pH
monitoring also revealed that for patients in Group 1, PLPR
mainly occurred at sleep stage, while for patients in Group
2, PLPR might exist with short intervals all day and last
longer at night (Fig. 5).
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Discussion
Up to now, esophagectomy with curative intent has been
regarded as the most effective treatment for early-stage
esophageal carcinoma [5–7]. Conventional approaches,
involving laparotomy and/or thoracotomy, are associated
with high incidence of morbidities, which delay the
recovery. Especially for upper esophageal carcinoma, cer-
vicothoracoabdominal esophagectomy is one of the most
complex surgical procedures with great trauma, making
some surgeons and patients dismay.
A great improvement in esophagectomy is the applica-
tion of minimally invasive techniques. Since Swanstrom
and Hansen introduced their experience on a completely
laparoscopic approach to esophageal cancer in 1997 [13],
the application of minimally invasive surgery for esopha-
geal cancer has become rapidly widespread in recent years.
CTLE has been performed in our department in 2009,
and it showed significant advantages over open procedure
in mortality and morbidity as other studies reported [14].
Due to the use of advanced instruments, current minimally
invasive esophagectomies hold normal laparoscopic or
thoracoscopic advantages. Both CTLE and LTE were
associated with short period of ICU and hospital stay,
relatively quick recovery, small incisions, and so on.
But in recent years, the aging demographics and the
growing number of the elderly patients with upper eso-
phageal carcinoma were becoming surgical problems we
faced. Could we develop other minimally invasive tech-
niques for upper esophageal carcinoma to decrease early
postoperative risk? Can we develop some kind of more
minimally invasive esophagectomy which the elderly or
patients with severe preoperative pulmonary dysfunction
Fig. 3 Disease-free survival curves between patients undergoing
LTE and CTLE
Fig. 4 Kaplan–Meier curves showing overall survival between
patients undergoing LTE and CTLE
Table 2 Comparisons of
postoperative complications
between the two groups
Group 1 (27 cases) Group 2 (56 cases) P Value
Complications 1 month after surgery 7 23 0.178
Pulmonary complications 2 8
Anastomotic leakage 3 8
Cardiac complications 2 7
Vocal-cord paralysis 0 1
herniation 1 0
Wound infection 1 4
Pulmonary complications 6 months after surgery 4 13 0.374
Anastomotic stricture 4 7 0.771
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could withstand? Would neoadjuvant chemotherapy be
helpful to improve long-term outcome of minimally inva-
sive esophagectomy without formal lymphadenectomy?
Based on the questions mentioned above, the gasless
laparoscopic transhiatal esophagectomy was developed.
Compared with CTLE, LTE had showed its own
advantages. First of all, the adverse effects of CO2 insuf-
flation and single-lung ventilation are eliminated. As life
expectancy rises in China, many patients 80 years old and
higher with esophageal cancer expect to prolong their life
by surgical treatment. These patients do not have adequate
pulmonary reserve [15], so it seems difficult for them to
tolerate pneumoperitoneum and single-lung ventilation.
The procedure of LTE has little to do with the thoracic
cavity and lung. So poor pulmonary function was no
obstacle to surgical treatment to upper esophageal
carcinoma any more. In Group 1, eight patients with low
pulmonary function (80 years old or greater) successfully
underwent LTE. LTE can be safely performed for upper
esophageal carcinoma with severe preoperative pulmonary
dysfunction. Secondly, the peritoneal cavity does not need
to be sealed airtight when performing LTE. This facilitates
several steps of the procedure. The operating time is
decreased because an optimal view can be maintained even
during irrigation suction. In our series, mean operative time
in Group 1 was only 131 ± 29 min, significantly lower
than that in Group 2 (P = 0.000). What is more, benefits of
LTE were also linked with a lower mean intraoperative
blood loss. Mean intraoperative blood loss of LTE was
only 189 ± 52 ml, even significantly lower than CTLE
(P = 0.001). Finally, severe PLPR happened less in Group
1 than that in Group 2. PLPR occurred every day in
Fig. 5 Comparison of postoperative 24-h pH monitoring 6 months after CTLE or LTE
Table 3 Multiple comparisons
of 24-h pH monitoring and
manometry (more than
6 months after surgery) between
Group 1 and Group 2: ðx sÞ
Group 1 (21 cases) Group 2 (45 cases) P value
Total number of reflux events (pH\ 4) 15.33 ± 2.82 28.76 ± 4.57 0.001
Number of reflux episodes (lasting[ 5 min) 5.19 ± 1.57 15.07 ± 1.85 0.000
The reflux time 2.28 ± 0.59 5.02 ± 0.50 0.000
The longest episode of reflux (min) 29.50 ± 4.83 22.51 ± 3.09 0.001
UESP (mm Hg) 12.34 ± 1.35 11.97 ± 1.00 0.217
UESL (cm) 1.88 ± 0.46 1.75 ± 0.34 0.227
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patients undergoing CTLE and LTE. PLPR had a major
effect on quality of life of patients experiencing
esophagectomy. High incidence of postoperative pul-
monary complications was mainly related to severe PLPR.
Tracking PLPR can provide important clues as to postop-
erative pulmonary complication and factors influencing
postoperative quality of life [16]. It should be noted that in
our series, incidence rates of postoperative pulmonary
complications, including those occurring within 30 post-
operative days and during follow-up, are relatively high. In
Group 2, 21 (37.5 %) patients had postoperative pulmonary
complications, while in Group 1, there were six (22.2 %)
patients having pulmonary complications at least one time
(P = 0.164). All the patients experiencing CTLE or LTE
complained about heartburn and regurgitation from time to
time. In Group 2, it was more severe than in Group 1. In
Group 1, PLPR mainly occurred at sleep stage, while for
patients in Group 2, PLPR might exist all the day only with
short intervals and last longer at night. This might lead to
higher incidence of postoperative pulmonary complications
in Group 2. Mediastinal tissue press may contribute to
reducing occurrence of PLPR and postoperative pulmonary
complications in patients undergoing LTE (Fig. 6).
For a long period of time, the transhiatal esophagectomy
has been regarded as a controversial procedure because of
failure to do extensive lymphadenectomy. In order to try to
decrease the possible influence of inadequate lymph-node
dissection, patients undergoing LTE in this study received
neoadjuvant and adjuvant chemotherapy. It is uncertain
whether neoadjuvant chemotherapy followed by
esophagectomy might lead to greater long-term survival
[17–19]. But survival analysis by Kaplan–Meier’s method
demonstrated that overall survival and disease-free survival
in Group 1 seem to be similar to those in Group 2. The
median overall survival of Group 1 and Group 2 reached up
to 30.8 and 27.2 months, respectively (P = 0.962). Fur-
thermore, neoadjuvant chemotherapy effectively
downstaging esophageal carcinoma with local advance was
observed in 11 cases. Downstaging these tumors made
them more resectable.
In conclusion, compared with CTLE, LTE is a more
minimally invasive approach to effectively treat patients
with upper esophageal carcinoma. Laryngo-pharyngeal
reflux after LTE was less severe than that after CTLE,
which might lower incidence of pulmonary complications.
For the elderly patients, LTE seems more suitable.
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